Close Menu

NEW YORK (360Dx) – Each year more Americans die from sepsis in the hospital than from any other cause.

To address this, a bolus of companies over the past year have plunged into the market, developing rapid tests to identify the condition that kills about 300,000 Americans each year. In December, Nanomix joined the mix, announcing it is developing a point-of-care test leveraging an electrochemical biosensor platform and enzyme- and immune-based assays to simultaneously probe for three biomarkers.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.